Biotech Scan
Scan
Biotech Scan
raw scan snapshot — prices as of scan date, not live 60 rows · screens, not recommendations
Data as-of 2026-07-06 close.
Biotech got MORE extended over the past ten sessions, not less — XBI/IBB/IBBQ all pushed deeper into overbought (RSI 77–79) and MRNA is now the single most extreme name in the whole scan (RSI 81.9, +114.7% above VWAP, up 71.9% in 30 days), with VRTX right behind it (RSI 81.6, near-ATH). The gene-editing basket (EDIT, NTLA, CRSP, ILMN, RXRX) broke out hard in the same window, while last cycle's "extended, don't chase" ATH names (ABBV, DHR, TMO) cooled off RSI without losing much price — healthy digestion, not a rollover. The only clean, non-frothy entries left are the same handful of large-cap basers: AMGN, GILD, TMO, BMRN.
Source: biotech-scan.json. Latest bar 2026-07-06. Prior scan: 2026-06-26-biotech-scan.
Quick Snapshot
| Signal | Reading |
|---|---|
| Overall | 🔴 Sector even more extended than 10 days ago — 3 ETFs (XBI 77, IBB 79.3, IBBQ 79.4) and 2 mega-caps (VRTX 81.6, MRNA 81.9) all print RSI > 76; MRNA is +114.7% above VWAP |
| Leaders | MRNA (RSI 81.9↑, +71.9% 30D, +114.7% vs VWAP — the most parabolic name in the dataset); LABU (RSI 77.7↑, 3x ETF, +146.1% vs VWAP); VRTX (RSI 81.6↑, near ATH, +19.6% 30D) |
| Laggards | LEGN (RSI 43.8, -11.0% 30D, weak-down GC); A (RSI 53.2, -3.35% 7D, cooling); REGN (RSI 57.4, still strong-down DC despite a bounce, -14.4% 3M) |
| Froth flags | MRNA +114.7% vs VWAP; LABU +146.1% vs VWAP (leveraged, do not initiate); PTGX +58.3%; KYMR +55.7%; ILMN +55.2% — five names now over +50% above their average holder |
| Key insight | The gene-editing cluster (EDIT RSI 70.8, NTLA 70.7, CRSP 69.6, ILMN 73.8, RXRX 68.4) all rerated together in the last 10 sessions — a real cohort move, not noise. Meanwhile the prior cycle's most-extended large-caps (ABBV 76.6→69, DHR 69.3→60.2, TMO 66.5→63.5) cooled their RSI while holding price — resting, not breaking. |
Price Table
| Stock | Price | RSI | vs SMA20 | 7D% | 30D% | 3M% | 52wkHi% | Trend | Signal |
|---|---|---|---|---|---|---|---|---|---|
| LEGN | $28.04 | 43.8 | -10.4% | +6.0% | -11.0% | +55.9% | -38.1% | weak-down GC | ⚠️ Caution |
| A | $130.60 | 53.2 | -0.2% | -3.4% | -1.4% | +14.9% | -18.5% | up DC | 🔍 Watch (cooling) |
| GILD | $129.61 | 54.5 | +3.0% | +4.3% | +1.9% | -6.0% | -17.6% | strong-up GC | 📈 Accumulate |
| BNTX | $93.93 | 54.9 | +3.5% | +5.4% | +9.9% | +4.8% | -24.3% | weak-up DC | 🔍 Watch |
| DXCM | $72.38 | 55.2 | +0.5% | +0.6% | -5.5% | +14.7% | -19.6% | strong-up GC | 🔍 Watch |
| BIIB | $208.46 | 56.2 | +2.9% | -0.2% | +8.2% | +18.7% | -5.1% | strong-up GC | 🔒 Hold |
| REGN | $649.81 | 57.4 | +4.6% | +3.1% | +6.3% | -14.4% | -20.9% | strong-down DC | ❌ Avoid (still DC) |
| ISRG | $432.83 | 59.9 | +5.3% | +3.6% | +3.4% | -4.4% | -28.3% | weak-up DC | 🔍 Watch (recovering) |
| DHR | $193.62 | 60.2 | +4.2% | +1.9% | +5.7% | +1.6% | -20.3% | weak-up DC | 🔍 Watch |
| BMRN | $58.79 | 60.7 | +3.5% | +1.5% | +4.0% | +4.6% | -11.3% | up DC | 📈 Accumulate |
| MDT | $83.06 | 60.9 | +3.8% | +2.4% | +3.9% | -3.0% | -21.9% | weak-up DC | 🔍 Watch |
| BEAM | $35.32 | 61.0 | +8.6% | -3.3% | +18.6% | +44.2% | -5.3% | strong-up GC | ⚠️ Extended |
| DNA | $10.11 | 61.4 | +11.8% | +1.8% | +25.0% | +48.2% | -42.5% | up DC | 🔍 Watch |
| NKTR | $73.15 | 62.0 | +16.5% | +12.5% | +29.2% | -4.1% | -32.9% | strong-up GC | 🔍 Watch (+27.7% vs VWAP) |
| SRPT | $19.18 | 62.9 | +14.6% | +15.8% | +23.3% | -16.9% | -24.3% | weak-up DC | 🔍 Watch (recovering) |
| AMGN | $366.44 | 63.0 | +4.1% | +3.6% | +6.0% | +8.6% | -6.4% | strong-up GC | 📈 Accumulate |
| TMO | $517.60 | 63.5 | +6.3% | +3.9% | +10.3% | +5.9% | -19.6% | weak-up DC | 📈 Accumulate |
| LLY | $1,200.06 | 64.0 | +4.3% | -1.0% | +4.4% | +29.1% | -3.1% | strong-up GC | 🔒 Hold |
| ALNY | $313.04 | 64.3 | +6.8% | +6.4% | +7.2% | -2.0% | -36.8% | weak-up DC | 🔍 Watch (recovering) |
| NVO | $49.26 | 66.1 | +8.0% | +4.8% | +20.1% | +33.5% | -31.4% | up DC | 📈 Accumulate |
| INCY | $115.62 | 67.6 | +8.1% | +2.3% | +14.9% | +23.4% | -2.6% | strong-up GC | 🔒 Hold |
| RXRX | $3.96 | 68.4 | +17.8% | +3.5% | +19.3% | +24.1% | -44.9% | weak-up DC | 🔍 Watch (-17.2% vs VWAP) |
| ABBV | $254.76 | 69.0 | +8.3% | +3.0% | +14.2% | +24.5% | -2.6% | up DC | 🔒 Hold |
| CRSP | $61.89 | 69.6 | +15.1% | +9.5% | +19.9% | +24.5% | -21.1% | up DC | 🔍 Watch |
| NTLA | $17.84 | 70.7 | +18.0% | +6.4% | +32.3% | +31.7% | -36.9% | strong-up GC | ⚠️ Extended |
| IONS | $83.18 | 70.7 | +8.7% | +0.6% | +13.1% | +12.6% | -4.1% | up DC | 🔒 Hold |
| EDIT | $3.65 | 70.8 | +29.3% | +17.0% | +38.3% | +33.2% | -19.6% | strong-up GC | ⚠️ Extended |
| IQV | $205.97 | 71.9 | +11.4% | +7.5% | +12.1% | +20.7% | -16.6% | up DC | 🔒 Hold |
| KYMR | $114.76 | 72.8 | +19.9% | +5.8% | +55.2% | +34.9% | -11.8% | strong-up GC | ⚠️ Extended (+55.7% vs VWAP) |
| ILMN | $194.33 | 73.8 | +14.3% | +5.9% | +23.0% | +53.7% | -0.4% | strong-up GC | ⚠️ Extended (+55.2% vs VWAP) |
| COGT | $39.44 | 73.9 | +11.8% | +2.3% | +26.6% | +10.7% | -9.8% | strong-up GC | ⚠️ Extended (+41.9% vs VWAP) |
| RARE | $33.70 | 76.5 | +21.9% | +9.0% | +56.1% | +45.6% | -20.5% | up DC | ⚠️ Extended (parabolic) |
| XBI | $160.81 | 77.0 | +11.7% | +2.6% | +25.3% | +24.9% | -0.5% | strong-up GC | ⚠️ Extended (+38.6% vs VWAP) |
| LABU | $304.95 | 77.7 | +35.4% | +7.7% | +91.6% | +79.0% | -1.3% | strong-up GC | 🔴 PARABOLIC (+146.1% vs VWAP) |
| PTGX | $131.50 | 78.5 | +14.0% | +9.5% | +34.1% | +26.8% | -1.0% | strong-up GC | ⚠️ Extended (+58.3% vs VWAP) |
| IBB | $195.31 | 79.3 | +9.4% | +3.8% | +17.0% | +15.9% | -0.4% | strong-up GC | ⚠️ Extended (+21.4% vs VWAP) |
| IBBQ | $33.58 | 79.4 | +9.2% | +4.2% | +16.8% | +16.4% | -0.7% | strong-up GC | ⚠️ Extended (+18.7% vs VWAP) |
| VRTX | $529.59 | 81.6 ↑ | +12.6% | +6.2% | +19.6% | +22.6% | -0.1% | strong-up GC | ⚠️ Extended (near ATH) |
| MRNA | $81.80 | 81.9 ↑ | +36.0% | +14.3% | +71.9% | +63.2% | -4.4% | strong-up GC | 🔴 PARABOLIC (+114.7% vs VWAP) |
Tier Analysis
Weak / Recovering (RSI < 60)
LEGN, A, REGN remain the scan's soft spots. REGN is still strong-down DC despite a +3.1% 7D bounce — don't read the bounce as a reversal. GILD, BNTX, DXCM, BIIB are unremarkable middle-of-the-road names. ISRG, ALNY, SRPT, DHR, MDT are all genuinely recovering off the prior "broken" tier (ISRG RSI 41.6→59.9, ALNY 49.4→64.3, SRPT 49.2→62.9 over the past 10 sessions) — improving but not yet clean entries.
Basing / Accumulate Candidates (RSI 60–67, not extended vs VWAP)
AMGN, GILD, TMO, BMRN, NVO are the cleanest setups in the scan — RSI 55–66, all still under +13% vs VWAP, none near a 52-week high. AMGN in particular has now held this basing pattern for two straight scans.
Momentum / Approaching Overbought (RSI 67–74)
INCY, ABBV, LLY, IONS, IQV, BIIB are extended but not broken — hold, don't add. The gene-editing cohort (RXRX, CRSP, NTLA, EDIT, ILMN) all jumped into this band together over the last 10 sessions; EDIT alone is +38.3% in 30 days. KYMR and COGT are frothier still (+42–56% vs VWAP).
Extended / Parabolic (RSI ≥ 76)
RARE, XBI, LABU, PTGX, IBB, IBBQ, VRTX, MRNA. Five of these eight are up double-digit RSI points and 8–35% in price since the 06-26 scan. MRNA and LABU are the two names to treat as exit/trim signals, not entries — both are >100% above VWAP.
Entry Zones
| Stock | Price | Zone | RSI | 30D% | Setup |
|---|---|---|---|---|---|
| AMGN | $366.44 | <$352 (SMA20 retest) | 63.0 | +6.0% | Cleanest large-cap accumulate two scans running; +12.8% vs VWAP |
| GILD | $129.61 | <$126 (SMA20 support) | 54.5 | +1.9% | Basing on SMA20/50/200; GC now confirmed; +3.5% vs VWAP |
| TMO | $517.60 | <$487 (SMA20) | 63.5 | +10.3% | Lab-tools; still weak-up DC but +10.3% 7D is the strongest print in two scans |
| BMRN | $58.79 | <$57 | 60.7 | +4.0% | Not extended (+4.4% vs VWAP); quiet, steady base |
| ISRG | $432.83 | Watch for GC flip | 59.9 | +3.4% | Two-scan recovery (RSI 41.6→59.9); still `weak-up DC` and -10.2% vs VWAP — wait for the cross before treating as a real entry |
Action Matrix
| Action | Stocks | Why |
|---|---|---|
| 📈 ACCUMULATE | AMGN, GILD, TMO, BMRN, NVO | RSI 55–66, none extended vs VWAP, best risk/reward in the sector |
| 🔒 HOLD | BIIB, LLY, INCY, IONS, IQV, ABBV | Uptrends intact, extended but not broken; don't add at these VWAP premiums |
| 🔍 WATCH | ISRG, ALNY, SRPT, DHR, MDT, DNA, RXRX, CRSP, BNTX, DXCM, NKTR | Mixed recoveries or mid-cycle names; wait for confirmation |
| ⚠️ EXTENDED / DON'T CHASE | NTLA, EDIT, KYMR, ILMN, COGT, RARE, XBI, PTGX, IBB, IBBQ, VRTX, BEAM | RSI 61–81.6, 18–58% above VWAP; sector re-rate is fully priced here |
| 🔴 PARABOLIC — TRIM/PROTECT | MRNA, LABU | +114.7% and +146.1% above VWAP respectively; do not initiate; trail stops if owned |
| ❌ AVOID | REGN, LEGN | Still in DC/weak-down regimes despite minor bounces |
What Changed Since Prior Scan (2026-06-26)
- MRNA went from "extreme" to "the most extreme name in the dataset." RSI 71.4→81.9, price +21.6% in 10 sessions, VWAP premium +82%→+114.7%. This is no longer a momentum trade to hold — it's a name that needs a real catalyst to hold current levels.
- VRTX crossed into the same tier. RSI jumped from 69.2 (stale bar) to 81.6 on a +10.3% price move — now the second-most extreme name in the scan, near ATH.
- The gene-editing basket broke out as a cohort. EDIT (RSI 53.4→70.8), NTLA (65.7→70.7), CRSP (57.4→69.6), RXRX (58.3→68.4), and ILMN (67.5→73.8) all re-rated together — a genuine sector rotation, not one-off noise.
- The prior cycle's most-extended large-caps cooled off without giving back much price. ABBV (RSI 76.6→69.0, price flat), DHR (69.3→60.2, -1.3%), TMO (66.5→63.5, +0.9%) — classic digestion. None of these broke down.
- ISRG, ALNY, SRPT continued recovering off the "broken" tier, each up 10+ RSI points over 10 sessions while gaining 3–14% in price. None have flipped to golden cross yet — still watch, not buy.
- Biotech ETFs (XBI/IBB/IBBQ) pushed deeper into overbought rather than resting — all three gained 3–5 RSI points and 3–5% in price. The ETF-level entry window from a month ago is fully closed.
Key Discoveries
| Discovery | Implication |
|---|---|
| Gene-editing basket (EDIT/NTLA/CRSP/RXRX/ILMN) moved as a cohort | Treat as one thesis bucket going forward, not five independent names |
| ABBV/DHR/TMO cooled RSI while holding price | "Resting after extended" ≠ "about to roll over" — the digestion pattern from the prior scan played out cleanly |
| MRNA/VRTX now the two most extreme names, replacing LABU/ABBV from the last cycle | Leadership in "most overbought" rotates every 10 days in this sector — don't anchor on last scan's list |
Mistakes (Don't Repeat)
| Mistake | Lesson |
|---|---|
| Assuming ABBV's RSI 76.6 in the prior scan meant an imminent pullback | It cooled to 69 on flat price instead — extended RSI in a strong-up name resolves via time, not always via price decline |
| Treating ISRG's "intact" thesis tag as static | It's now recovering (RSI 41.6→59.9) — the thesis tag needs re-checking each scan, not carried forward unread |
Open Questions
- MRNA at +114.7% vs VWAP: is there a pipeline catalyst that justifies holding, or is this pure momentum that mean-reverts hard on any miss?
- Gene-editing cohort: is this a durable re-rate (regulatory/clinical) or a beta trade riding XBI's overbought run?
- ISRG/ALNY/SRPT: do any of these actually flip to golden cross in the next scan, or do they stall mid-recovery?
Related
10 eventsNo direct external sources are attached to this read.